Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: A propensity score matching study

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Hu, Hao ^a   Duan, Zhenhua ^b   Long, Xiaoran ^c   Hertzanu, Yancu ^d   Shi, Haibin ^a   Liu, Sheng ^a   Yang, Zhengqiang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Chengdu Center for Disease Control and Prevention   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; SELECTION BIAS; SKIN MANIFESTATION; SURVIVAL TIME; TUMOR GROWTH; TUMOR INVASION; VASCULAR TUMOR; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SKIN DISEASES; STATISTICS AND NUMERICAL DATA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DIARRHEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NIACINAMIDE; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLUREA COMPOUNDS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SKIN DISEASES;

EID: 84901236146     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096620     Document Type: Article

References (29)

1. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750. (Pubitemid 29114292)
2. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. (Pubitemid 32911406)
3. Liao M, Huang J, Zhang T, Wu H (2013) Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One 8(7):e68453.doi: 10.1371/journal.pone.0068453.
4. Takayasu K, Arii S, Ikai I, Omata M, Okita K, et al. (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469. (Pubitemid 44142456)
5. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, et al. (2010) Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Roentgenol 194: 830-837.
6. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, et al. (2011) Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 18: 413-420.
7. Chung GE, Lee JH, Kim HY, Kim HY, Hwang SY, et al. (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258: 627-634.
8. Lee S, Kim BK, Kim SU, Park Y, Chang S, et al. (2013) Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One 8(10):e77240.doi: 10.1371/journal.pone.0077240.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, SHARP Investigators Study Group, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med359: 378-390.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
12. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, et al. (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug eluting beads for hepatocellular carcinoma. J Clin Oncol 29(30):3960-3967.
13. Park JW, Koh YH, Kim HB, Kim HY, An S, et al. (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 56(6):1336-1342.
14. Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022.
15. Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, et al. (2011) Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol 17(2):113-119.
16. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika70:41-55.
17. Leuven E, Sianesi B (2003) PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Statistical software components.Boston College Department of Economics.
18. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, et al. (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163(3):262-270. (Pubitemid 43145754)
19. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, et al. (2009) Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 24(5):806-814.
20. Georgiades CS, Hong K, D9Angelo M, Geschwind JF (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16(12):1653-1659. (Pubitemid 44431162)
21. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, et al. (1997) The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 79(11):2087-2094. (Pubitemid 27227372)
22. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, et al. (2012) Advanced stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263(2):590-599.
23. Okusaka T, Okada S, Ishii H, Nose H, Nagahama H et al. (1997) Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 44(13):251-257. (Pubitemid 27096048)
24. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, et al. (2007) Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 13(3):414-420. (Pubitemid 46178976)
25. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908-943.
26. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, et al. (2013) Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study. J Digestive Diseases.14181190
27. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47(14):2117-27.
28. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, et al. (2013) Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 5(7): 364-371.
29. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, et al. (2012) Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 82(2):119-125.